Published in J Biol Chem on October 25, 2011
Alteration of fatty-acid-metabolizing enzymes affects mitochondrial form and function in hereditary spastic paraplegia. Am J Hum Genet (2012) 1.71
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci (2012) 1.27
The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J Neuroimmune Pharmacol (2012) 1.06
The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors. Br J Pharmacol (2012) 0.95
Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry (2013) 0.88
Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice. Br J Pharmacol (2013) 0.88
Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells. Br J Pharmacol (2012) 0.86
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol (2013) 0.85
The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons. Pharmacol Res (2012) 0.84
Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. J Biol Chem (2014) 0.83
Inhibition of COX-2-mediated eicosanoid production plays a major role in the anti-inflammatory effects of the endocannabinoid N-docosahexaenoylethanolamine (DHEA) in macrophages. Br J Pharmacol (2014) 0.83
(R,R')-4'-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility. Biochem Pharmacol (2013) 0.82
Emerging targets in lipid-based therapy. Biochem Pharmacol (2012) 0.81
The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists. PLoS One (2013) 0.80
The roles of sphingosine kinase 1 and 2 in regulating the metabolome and survival of prostate cancer cells. Biomolecules (2013) 0.79
GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis. Br J Pharmacol (2015) 0.79
Lysophospholipid Receptors, as Novel Conditional Danger Receptors and Homeostatic Receptors Modulate Inflammation-Novel Paradigm and Therapeutic Potential. J Cardiovasc Transl Res (2016) 0.78
Two Janus cannabinoids that are both CB2 agonists and CB1 antagonists. J Pharmacol Exp Ther (2016) 0.77
Role of GPR55 during Axon Growth and Target Innervation(1,2,3). eNeuro (2015) 0.77
The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects. Br J Pharmacol (2015) 0.76
An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol. Front Pharmacol (2017) 0.75
The cannabinoid CB2 agonist GW405833 suppresses inflammatory and neuropathic pain through a CB1 mechanism that is independent of CB2 receptors in mice. J Pharmacol Exp Ther (2017) 0.75
Quantitative analyses of synergistic responses between cannabidiol and DNA-damaging agents on the proliferation and viability of glioblastoma and neural progenitor cells in culture. J Pharmacol Exp Ther (2016) 0.75
Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog Chem Org Nat Prod (2017) 0.75
A putative lysophosphatidylinositol receptor GPR55 modulates hippocampal synaptic plasticity. Hippocampus (2017) 0.75
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet (2006) 6.50
Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta (2010) 4.99
Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet (2007) 4.47
The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol (2007) 4.22
Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol (2007) 4.02
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev (2008) 2.75
CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol (2010) 2.74
ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J Neurosci (2002) 2.60
Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol (2005) 2.42
GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A (2008) 2.42
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun (2007) 2.18
Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A (2008) 1.97
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.87
The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J (2008) 1.83
Oxidative neuronal injury. The dark side of ERK1/2. Eur J Biochem (2004) 1.81
Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage (2009) 1.67
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A (2009) 1.63
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther (2006) 1.61
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60
The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain (2008) 1.54
Inflammation persistently enhances nocifensive behaviors mediated by spinal group I mGluRs through sustained ERK activation. Pain (2004) 1.49
Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci (2008) 1.48
Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci (2004) 1.40
GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol (2010) 1.39
The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene (2010) 1.36
The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene (2010) 1.32
B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts. Mol Cell Biol (2004) 1.28
Screening for inhibitors of low-affinity epigenetic peptide-protein interactions: an AlphaScreen-based assay for antagonists of methyl-lysine binding proteins. J Biomol Screen (2009) 1.27
Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther (2007) 1.27
Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther (2008) 1.25
ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. J Biol Chem (2003) 1.25
Differential changes in GPR55 during microglial cell activation. FEBS Lett (2009) 1.24
A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol (2010) 1.21
Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biol (2010) 1.15
B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization. Mol Biol Cell (2007) 1.15
Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol (2009) 1.08
Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol (2009) 1.07
Novel high-throughput screening system for identifying STAT3-SH2 antagonists. Biochem Biophys Res Commun (2009) 1.02
Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol (2009) 1.00
Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther (2010) 1.00
Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry (2011) 1.00
Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol Interv (2009) 0.99
B-RAF inhibitors: an evolving role in the therapy of malignant melanoma. Curr Oncol Rep (2010) 0.97
CRP is a novel ligand for the oxidized LDL receptor LOX-1. Am J Physiol Heart Circ Physiol (2009) 0.96
GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells. Br J Pharmacol (2010) 0.95
Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br J Pharmacol (2009) 0.95
Cannabinoid type 2 receptor as a target for chronic - pain. Mini Rev Med Chem (2009) 0.93
Development of high-throughput TR-FRET and AlphaScreen assays for identification of potent inhibitors of PDK1. J Biomol Screen (2009) 0.93
Prolonged activation of ERK triggers glutamate-induced apoptosis of astrocytes: neuroprotective effect of FK506. J Neurochem (2010) 0.92
Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem (2010) 0.91
Recent advances in the research and development of B-Raf inhibitors. Curr Med Chem (2010) 0.88
Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain. Osteoarthritis Cartilage (2010) 0.86
Development of cell-based assays for cytokine receptor signaling, using an AlphaScreen SureFire assay format. Anal Biochem (2010) 0.84
Functional polymorphism in the GPR55 gene is associated with anorexia nervosa. Synapse (2011) 0.82
Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice. Eur J Pharmacol (2010) 0.82
Influence of nicotinic receptor modulators on CB2 cannabinoid receptor agonist (JWH133)-induced antinociception in mice. Behav Pharmacol (2007) 0.81
Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol (2005) 2.42
Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science (2007) 2.21
Mitochondrial CB₁ receptors regulate neuronal energy metabolism. Nat Neurosci (2012) 2.15
Leptin regulates AMPA receptor trafficking via PTEN inhibition. J Neurosci (2010) 1.91
GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem (2004) 1.91
Pregnenolone can protect the brain from cannabis intoxication. Science (2014) 1.85
The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J (2008) 1.83
Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med (2007) 1.69
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A (2009) 1.63
Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int (2008) 1.62
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol (2005) 1.60
Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res (2008) 1.60
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med (2005) 1.56
Leptin promotes rapid dynamic changes in hippocampal dendritic morphology. Mol Cell Neurosci (2007) 1.55
Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem (2006) 1.54
GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol (2010) 1.39
Cross-cultural comparisons of medicinal floras--what are the implications for bioprospecting? J Ethnopharmacol (2011) 1.38
Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol (2002) 1.31
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol (2007) 1.30
CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol (2012) 1.26
Anticancer drugs from nature--natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep (2007) 1.24
A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol (2010) 1.21
An essential role for constitutive endocytosis, but not activity, in the axonal targeting of the CB1 cannabinoid receptor. Mol Pharmacol (2006) 1.20
Astrocytic adenosine kinase regulates basal synaptic adenosine levels and seizure activity but not activity-dependent adenosine release in the hippocampus. Neuropharmacology (2008) 1.18
Inhibitory effect of ethanol on AMPK phosphorylation is mediated in part through elevated ceramide levels. Am J Physiol Gastrointest Liver Physiol (2010) 1.18
Leptin inhibits rat hippocampal neurons via activation of large conductance calcium-activated K+ channels. Nat Neurosci (2002) 1.16
Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol (2007) 1.15
(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol (2002) 1.14
Leptin induces a novel form of NMDA receptor-dependent long-term depression. J Neurochem (2005) 1.14
Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther (2002) 1.13
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol (2015) 1.12
Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci (2009) 1.12
Leptin-induced dynamic alterations in the actin cytoskeleton mediate the activation and synaptic clustering of BK channels. FASEB J (2005) 1.11
Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. Br J Pharmacol (2004) 1.10
Effect of ethanol on hydrogen peroxide-induced AMPK phosphorylation. Am J Physiol Gastrointest Liver Physiol (2008) 1.10
6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur J Pharmacol (2004) 1.09
Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol (2009) 1.08
Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis (2010) 1.08
Yucatec Mayan medicinal plants: evaluation based on indigenous uses. J Ethnopharmacol (2002) 1.06
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J Neurosci Res (2011) 1.03
Phytocannabinoids beyond the Cannabis plant - do they exist? Br J Pharmacol (2010) 1.03
Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma (2006) 1.03
In silico target fishing for rationalized ligand discovery exemplified on constituents of Ruta graveolens. Planta Med (2008) 1.02
The major central endocannabinoid directly acts at GABA(A) receptors. Proc Natl Acad Sci U S A (2011) 1.02
Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology (2004) 1.01
Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. J Med Chem (2003) 1.01
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol (2010) 1.01
A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J Endocrinol (2011) 1.00
Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A (2013) 1.00
Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem Biol (2011) 0.99
Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol (2010) 0.98
Imipramine blocks ethanol-induced ASMase activation, ceramide generation, and PP2A activation, and ameliorates hepatic steatosis in ethanol-fed mice. Am J Physiol Gastrointest Liver Physiol (2011) 0.98
Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. Neuropharmacology (2005) 0.98
Synthesis of (-)-dactylolide and 13-desmethylene-(-)-dactylolide and their effects on tubulin. Org Lett (2010) 0.97
Differential subcellular localization of RIC-3 isoforms and their role in determining 5-HT3 receptor composition. J Biol Chem (2007) 0.97
Synergistic immunomopharmacological effects of N-alkylamides in Echinacea purpurea herbal extracts. Int Immunopharmacol (2009) 0.96
The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes (2011) 0.96
Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. Bioorg Med Chem (2005) 0.96
Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem (2012) 0.96
Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. Diabetes (2009) 0.95
Both mGluR1 and mGluR5 mediate Ca2+ release and inward currents in hippocampal CA1 pyramidal neurons. Neuropharmacology (2004) 0.95
Identification of serotonin 5-HT1A receptor partial agonists in ginger. Bioorg Med Chem (2010) 0.95
The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharmacology (2002) 0.94
Long-range regulatory synergy is required to allow control of the TAC1 locus by MEK/ERK signalling in sensory neurones. Neurosignals (2010) 0.94
Quinolizidine alkaloids from the curare adjuvant Clathrotropis glaucophylla. Phytochemistry (2002) 0.94
Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies? J Pharm Pharmacol (2009) 0.94
Dynamic imaging of cannabinoid receptor 1 vesicular trafficking in cultured astrocytes. ASN Neuro (2009) 0.94
Generation and functional characterization of fluorescent, N-terminally tagged CB1 receptor chimeras for live-cell imaging. Mol Cell Neurosci (2007) 0.94
Multiple actions of anandamide on neonatal rat cultured sensory neurones. Br J Pharmacol (2004) 0.94
Endocannabinoid content in fetal bovine sera - unexpected effects on mononuclear cells and osteoclastogenesis. J Immunol Methods (2011) 0.93
Plant volatiles: production, function and pharmacology. Nat Prod Rep (2011) 0.93
Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats. Psychopharmacology (Berl) (2007) 0.92
Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol (2007) 0.92
Catalytic selective cyclizations of aminocyclopropanes: formal synthesis of aspidospermidine and total synthesis of goniomitine. Angew Chem Int Ed Engl (2010) 0.92
Total synthesis of hypermodified epothilone analogs with potent in vitro antitumor activity. Org Lett (2008) 0.92
Evidence for bidirectional endocannabinoid transport across cell membranes. J Biol Chem (2012) 0.91
Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling. J Biol Chem (2013) 0.91
Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc Chem Res (2007) 0.91
Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. ACS Chem Neurosci (2012) 0.90
Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors. J Med Chem (2012) 0.89
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology (Berl) (2011) 0.88
Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem Biophys Res Commun (2005) 0.88
Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. Br J Pharmacol (2012) 0.88
Structure-activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections. J Med Chem (2010) 0.88
GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr Top Med Chem (2010) 0.88
Conformational preferences of natural and C3-modified epothilones in aqueous solution. J Med Chem (2008) 0.88